

- Affinity-based mass spectrometry,
 biomarkers, 191–198
- Albumin, human plasma analysis, 221
- Amide hydrogen/deuterium exchange, 133
- Antibodies, hydrogen/deuterium exchange
 mass spectrometry, 152
- Antigen arrays, protein activity arrays and,
 protein arrays, 289
- Arrays. *See* Protein arrays
- Automation, bioinformatics, 256–258
- Backbone amide hydrogens,
 hydrogen/deuterium exchange mass
 spectrometry, 134
- Biochemical and display methods (chemical
 genomics), 234–245
 display types, 240–244
 generally, 234–237
 intracellular drug-protein interactions
 detection, 244–245
 selection criteria, 237–239
- Bioinformatics, 249–272
 automation and high throughput, 256–258
 complexity factor, 251–253
 complexity reduction strategies, 260–263
 data exchange, 268
 data warehouse integration strategies,
 263–264
 experimental results and, 265–268
 future prospects, 268–269
 human plasma analysis, 227
 mass spectrometric analysis, 253–256
 overview, 249–251
 protein identification, 46–49
 protein-protein interaction mapping, 77
 protein sequence databases, 258–260
 quality control, protein-protein interaction
 mapping, 73–77
- Biomarker discovery pipeline integration,
 protein arrays, 288–289
- Biomarkers, 181–216
 defense mechanisms and diagnostics,
 203–205
 drug development, 205–209
 mass-spectrometry-based approaches,
 184–187
 affinity-based, 187–198
 overview, 181–184
 phosphoproteome analysis, 187–190
 protein complexes, signaling pathways
 and, 190–191
 protein quantitation, 198–203
- Blot digestion, protein processing, 18–19
- Cathepsin B inhibitor design, high-
 throughput crystallography/in silico
 methods, 125
- Cell culture, protein purification, 8
- Cell subpopulations, protein purification,
 10–11
- Cell surface display, chemical genomics, 243
- Chemical genomics, 231–248
 biochemical and display methods, 234–245
 compound immobilization, 239–240
 display types, 240–244
 generally, 234–237
 intracellular drug-protein interactions
 detection, 244–245
 selection criteria, 237–239
 discussion of, 245
 overview, 231–233
 phenotype-based methods, 233–234

- Cloning, high-throughput crystallography/in silico methods, 109–110
- Colicin E9, metal and protein complexes of, hydrogen/deuterium exchange mass spectrometry, 144
- Co-localization, protein-protein interaction mapping, 80
- Column fabrication, high-performance liquid chromatography, 38–40
- Complexity factor, bioinformatics, 251–253
- Complexity reduction strategies, bioinformatics, 260–263
- Compound immobilization, chemical genomics, biochemical and display methods, 239–240
- Construct selection, high-throughput crystallography/in silico methods, 109–110
- Continuous-infusion spectrometers, electrospray ionization mass spectrometry, 35–36
- Conventional high-performance liquid chromatography, 37
- COOH-terminal Src kinase, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 149
- C-termini labeling, protein-protein interaction mapping, bioinformatic quality control, 73
- Cyclic adenosine-5-phosphate-dependent kinase, hydrogen/deuterium exchange mass spectrometry, 148–149, 150
- Databases, protein sequence, bioinformatics, 258–260
- Data exchange, bioinformatics, 268
- Defense mechanisms, diagnostics and, biomarkers, 203–205
- Deoxyribonucleic acid, to ribonucleic acid, 4–6
- Detection technologies, protein arrays, 281–283
- Deuterium sublocalization, by MS/MS, hydrogen/deuterium exchange mass spectrometry, 139
- Diagnostics, defense mechanisms and, biomarkers, 203–205
- Differential display, protein targets identification, 162–163
- Digestion, in-gel, protein processing, 19
- Digestion optimization, hydrogen/deuterium exchange mass spectrometry, 136, 139
- Display methods. *See* Biochemical and display methods (chemical genomics)
- Docking (high-throughput crystallography/in silico methods), 119–122
- high throughput, 119–120
- low throughput, 121–122
- medium throughput, 120–121
- Doxorubicin, phage display, chemical genomics, 241
- Drug development, biomarkers, 205–209
- Edman degradation, protein identification, 19–20
- Electrospray ionization mass spectrometry:
- high-performance liquid chromatography coupling, 41–42
- protein identification, 27–46
- Electrospray ionization mass spectrometry-phosphopeptide-specific liquid chromatography, protein posttranslational modifications, 87–88
- Electrospray-mass spectrum-based phosphorylation site mapping, of Pho4, 89–93
- Expression profiling (protein arrays), 285–289
- biomarker discovery pipeline integration, 288–289
- focused arrays, 288
- protein activity and antigen arrays, 289
- specificities number, 285–287
- First-pass mapping, protein-protein interaction mapping, 78–79
- FK506 example, phage display, chemical genomics, 240–241
- Focused arrays, expression profiling, 288
- Fourier transform mass spectrometry, proteomics, 53–54
- Full-length proteins, protein-protein interaction mapping, 66–68

- Gel electrophoresis:
 human plasma analysis, 222–223
 one-dimensional, protein targets
 identification, 161–162
 two-dimensional:
 postlabeling, protein detection, 16–17
 prelabeling, protein detection, 15–16
 protein targets identification,
 separation/identification, 162
- Gel-free analysis:
 protein targets identification, 164–165
 proteomics, 50–54
- Global internal standard technology, protein
 targets identification, 169–170
- Glutathione-thioredoxin conjugates,
 hydrogen/deuterium exchange mass
 spectrometry, 143–144
- Glycosylation, posttranslational
 modifications, 168–169
- Hemoglobin, hydrogen/deuterium exchange
 mass spectrometry, 148
- High-performance liquid chromatography,
 37–43
 conventional, 37
 electrospray mass spectrometer coupling,
 41–42
 hydrogen/deuterium exchange mass
 spectrometry, 139
 microflow, 37–40
 peptide mass spectrometry applications,
 42–46
 setup, 40–41
- High-throughput analysis, bioinformatics,
 256–258. *See also* Hydrogen/
 deuterium exchange mass
 spectrometry
- High-throughput crystallography/in silico
 methods, 107–129
 cathepsin B inhibitor design, 125
 construct selection, cloning, and
 microscreening, 109–110
 data tracking, 116
 docking, 119–122
 high throughput, 119–120
 low throughput, 121–122
 medium throughput, 120–121
 drug design examples, 122–123
 overview, 108–109
 protein expression, 110–111
 robotic nanovolume crystallization and
 imaging, 111–113
 structure analysis, 116–119
 multiple structures, 118–119
 single structure, 117–118
 structure determination and refinement,
 115–116
 structure prediction, 123–125
 X-ray data collection, 114–115
- Human cell transfection, protein-protein
 interaction mapping, 68
- Human growth hormone, pH-dependent
 conformations of,
 hydrogen/deuterium exchange mass
 spectrometry, 147
- Human plasma analysis, 217–229
 abundant proteins depletion, 221
 bioinformatics, 227
 industrial scale, defined, 219–220
 intact protein versus peptides separation,
 223–225
 mass spectrometry, 226–227
 overview, 217–219
 protein size considerations, 222
 sample selection, collection, and pooling,
 220–221
- Hybrid mass spectrometers, electrospray
 ionization mass spectrometry, 34
- Hydrogen/deuterium exchange mass
 spectrometry, 131–157
 applications with fragmentation, 146–152
 antibodies, 152
 hemoglobin, 148
 kinases and phosphatases, 148–151
 protein-carbohydrate interactions, 151
 therapeutic proteins analysis, 146–148
 applications without fragmentation,
 143–146
 colicin E9, metal and protein complexes
 of, 144
 glutathione-thioredoxin conjugates,
 143–144
 mechanism of, 145
 membrane proteins, 146
 protein stability titration curves, 145
 retinoic acid binding protein-ligand
 interactions, 144
 whey proteins, 144–145

- overview, 132–133
- technologies, 134–143
 - automation by mass spectrometry, 140–143
 - deuterium sublocalization by MS/MS, 139
 - digestion optimization, 136, 139
 - generally, 134–135
 - high-performance liquid chromatography separation, 139
 - matrix-assisted laser desorption ionization methods, 139–140
 - on-exchange, 136, 137–138
 - protein fragmentation by proteolysis, 136
 - quench of reaction, 136
- theory, 133–134
 - amide hydrogen/deuterium exchange, 133
 - backbone amide hydrogens, 134
 - protection factor, 133
- Imaging:
 - robotic nanovolume crystallization and, high-throughput crystallography/in silico methods, 111–113
 - X-ray data collection, high-throughput crystallography/in silico methods, 114–115
- Industrial scale, defined, human plasma, 219–220
- In silico methods. *See* High-throughput crystallography/in silico methods
- Interferon- γ , hydrogen/deuterium exchange mass spectrometry, therapeutic proteins analysis, 147–148
- Interleukin-6 antibodies, hydrogen/deuterium exchange mass spectrometry, 152
- Intracellular drug-protein interactions
 - detection, chemical genomics, 244–245
- Ion cyclotron mass spectrometer, electrospray ionization mass spectrometry, 32–34
- Ion trap mass spectrometer, electrospray ionization mass spectrometry, 30–32
- Isotope-coded affinity tags, protein targets identification, 169
- Kinases, phosphatases and, hydrogen/deuterium exchange mass spectrometry, 148–151
- LC-ES-MS/MS, targeted phosphopeptide sequencing and phosphosite mass spectrometry Western analysis by, protein posttranslational modifications, 88–89
- Liquid chromatography, phosphopeptide-specific-electrospray ionization mass spectrometry, protein posttranslational modifications, 87–88
- Liquid chromatography tandem mass spectrometry, multidimensional, protein targets identification, 165
- Liquid protein arrays, solid versus, 275–277
- Low throughput, docking, high-throughput crystallography/in silico methods, 121–122
- MALDI. *See* Matrix-assisted laser desorption ionization methods (MALDI)
- Mass-coded abundance tags, protein targets identification, 170
- Mass spectrometry. *See also* Hydrogen/deuterium exchange mass spectrometry; Protein posttranslational modifications
 - automation by, hydrogen/deuterium exchange mass spectrometry, 140–143
 - bioinformatics, 253–256
 - biomarkers, 184–187
 - affinity-based, 191–198
 - human plasma analysis, 226–227
 - protein identification, 20–26
 - sample preparation for, protein-protein interaction mapping, 69–70
 - spectrometers for, protein-protein interaction mapping, 70–71
- Matrix-assisted laser desorption ionization methods (MALDI):
 - biomarkers, affinity-based mass spectrometry, 187–198
 - hydrogen/deuterium exchange mass spectrometry, 139–140

- of phosphorylated peptides, protein posttranslational modifications, 88
- to phosphorylation site mapping, protein posttranslational modifications, 93–96
- protein identification, 20–26
- Medium throughput, docking, high-throughput crystallography/in silico methods, 120–121
- Membrane proteins, hydrogen/deuterium exchange mass spectrometry, applications without fragmentation, 146
- Messenger RNA display, chemical genomics, 241–242
- Methylation, protein targets identification, 170
- Microbead display, chemical genomics, 244
- Microflow high-performance liquid chromatography, 37–40
- Microscreening, high-throughput crystallography/in silico methods, 109–110
- Molecular biology, protein-protein interaction mapping, 65–68
- MS/MS. *See* Tandem mass spectrum (MS/MS)
- N-terminal labeling:
 - isotope tagging, of protein digests, protein posttranslational modifications, 89
 - protein-protein interaction mapping, bioinformatic quality control, 73
- Nuclear magnetic resonance, hydrogen/deuterium exchange mass spectrometry compared, therapeutic proteins analysis, 147
- One-dimensional gel electrophoresis, protein targets identification, separation/identification, 161–162
- On-exchange, hydrogen/deuterium exchange mass spectrometry technologies, 136, 137–138
- Peptide masses, MS/MS spectra and, protein-protein interaction mapping, protein identification based on, 71–73
- Peptide mass spectrometry, high-performance liquid chromatography applications, 42–46
- Peptide mixtures, introduction techniques, electrospray ionization mass spectrometry, 34–35
- Peptides separation, intact protein separation versus, human plasma analysis, 223–225
- Phage display, chemical genomics, 240–241
- pH-dependent conformations, of human growth hormone, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 147
- Phenotype-based methods, chemical genomics, 233–234
- Phosphatases, kinases and, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 148–151
- Phosphatase treatment, of phosphorylated peptides, protein posttranslational modifications, 88
- Phosphopeptide selective precursor ion scanning, protein posttranslational modifications, 88
- Phosphopeptide sequencing, targeted and phosphosite mass spectrometry Western analysis by LC-ES-MS/MS, 88–89
- Phosphopeptide-specific liquid chromatography-electrospray ionization mass spectrometry, 87–88
- Phosphoproteome analysis, biomarkers, 187–190
- Phosphorylated peptides:
 - MALDI analysis of, protein posttranslational modifications, 88
 - phosphatase treatment of, protein posttranslational modifications, 88
- Phosphorylation, posttranslational modifications, protein targets identification, 165, 167–168
- Phosphorylation site mapping, MALDI-based approaches, protein posttranslational modifications, 93–96. *See also* Protein posttranslational modifications

- Phosphosite mass spectrometry, targeted phosphopeptide sequencing and Western analysis by LC-ES-MS/MS, protein posttranslational modifications, 88–89
- Plasma. *See* Human plasma analysis
- Plasmid display, chemical genomics, 242–243
- Postlabeling, protein detection, two-dimensional gel electrophoresis (protein separation), 16–17
- Posttranslational modifications, protein targets identification, 165–169
- Precursor ion scanning, phosphopeptide selective, protein posttranslational modifications, 88
- Prelabeling, protein detection, two-dimensional gel electrophoresis (protein separation), 15–16
- Protein(s):
full-length, protein-protein interaction mapping, 66–68
ribonucleic acid to, 6
size considerations, human plasma analysis, 222
therapeutic proteins analysis, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 146–148
- Protein activity arrays, antigen arrays and, protein arrays, 289
- Protein arrays, 273–294
configurations of, 274–275
content, 283–285
detection technologies, 281–283
expression profiling, 285–289
biomarker discovery pipeline integration, 288–289
focused arrays, 288
protein activity and antigen arrays, 289
specificities number, 285–287
future prospects, 289–290
overview, 274
solid versus liquid, 275–277
spotting technologies, 279–280
surfaces optimization, 277–279
- Protein-carbohydrate interactions, hydrogen/deuterium exchange mass spectrometry, 151
- Protein complexes, signaling pathways and, biomarkers, 190–191
- Protein detection, two-dimensional gel electrophoresis (protein separation), 15–17
- Protein digests, N-terminal isotope tagging (NIT) labeling of, protein posttranslational modifications, 89
- Protein expression, high-throughput crystallography/in silico methods, 110–111
- Protein fragmentation:
protein-protein interaction mapping, 66–68
by proteolysis, hydrogen/deuterium exchange mass spectrometry, 136
- Protein identification, 19–49
bioinformatics, 46–49
Edman degradation, 19–20
hybrid instruments, 26–46
mass spectrometers for, protein-protein interaction mapping, 70–71
mass spectrometry, 20–26
peptide masses and MS/MS spectra, protein-protein interaction mapping, 71–73
- Protein phosphorylation, quantitative analysis of, protein posttranslational modifications, 96–102
- Protein posttranslational modifications, 85–106
experimental, 87–89
MALDI analysis, of phosphorylated peptides, 88
N-terminal isotope tagging (NIT) labeling of protein digests, 89
phosphopeptide selective precursor ion scanning, 88
phosphopeptide-specific liquid chromatography-electrospray ionization mass spectrometry, 87–88
phosphorylated peptides, phosphatase treatment of, 88
targeted phosphopeptide sequencing and phosphosite mass spectrometry Western analysis by LC-ES-MS/MS, 88–89
overview, 86–87

- results, 89–102
 - ES-MS-based phosphorylation site mapping of Pho4, 89–93
 - MALDI-based approaches to phosphorylation site mapping, 93–96
 - protein phosphorylation, quantitative analysis of, 96–102
- Protein processing, 17–19
 - blot digestion, 18–19
 - in-gel digestion, 19
- Protein-protein interaction mapping, 63–84
 - experimental design, 77–80
 - change focus, 79–80
 - first-pass mapping, 78–79
 - methodology, 64–77
 - bioinformatic quality control, 73–77
 - bioinformatics on, 77
 - generally, 64–65
 - human cell transfection, 68
 - mass spectrometry:
 - sample preparation for, 69–70
 - spectrometers for, 70–71
 - molecular biology, 65–68
 - peptide masses and MS/MS spectra, protein identification based on, 71–73
 - protein separation, 68–69
 - overview, 64
- Protein purification, 6–12
 - cell culture, 8
 - complex samples, 8–10
 - generally, 6–8
 - subcellular components, 11–12
 - subpopulation of cells, 10–11
- Protein quantitation, biomarkers, 198–203
- Protein separation:
 - protein-protein interaction mapping, 68–69
 - two-dimensional gel electrophoresis, 12–17
 - principles of, 13–15
 - protein detection, 15–17
- Protein sequence databases, bioinformatics, 258–260
- Protein stability titration curves, hydrogen/deuterium exchange mass spectrometry, 145
- Protein targets identification, 159–180
 - informatics, 173–174
 - overview, 159–161
 - tools, 161–170
 - quantification, 169–170
 - separation/identification, 161–169
 - differential display, 162–163
 - gel-free methods, 164–165
 - liquid chromatography tandem mass spectrometry, multidimensional, 165
 - one-dimensional gel electrophoresis, 161–162
 - pathway mapping, 163–164
 - posttranslational modifications, 165–169
 - two-dimensional gel electrophoresis, 162
 - validation, 170–173
 - in vitro techniques, 171–172
 - in vivo techniques, 172–173
- Protein-tyrosine phosphatase 1B,
 - hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 149, 151
- Proteolysis, protein fragmentation by, hydrogen/deuterium exchange mass spectrometry, 136
- Proteomics, 1–62
 - challenges in, 46–54
 - classical, 46–50
 - Fourier transform mass spectrometry, 53–54
 - gel-free analysis, 50–53
 - overview, 2–6
 - deoxyribonucleic acid to ribonucleic acid, 4–6
 - ribonucleic acid to protein, 6
 - protein identification, 19–49
 - bioinformatics, 46–49
 - Edman degradation, 19–20
 - hybrid instruments, 26–46
 - mass spectrometry, 20–26
 - protein processing, 17–19
 - blot digestion, 18–19
 - in-gel digestion, 19
 - protein purification, 6–12
 - cell culture, 8
 - complex samples, 8–10
 - generally, 6–8
 - subcellular components, 11–12

- subpopulation of cells, 10–11
- protein separation (two-dimensional gel electrophoresis), 12–17
 - principles of, 13–15
 - protein detection, 15–17
 - proteome handling, 6
- Quench of reaction, hydrogen/deuterium exchange mass spectrometry technologies, 136
- Reciprocal mass spectrometry, protein-protein interaction mapping, 80
- Repeat immunopurification, protein-protein interaction mapping, 73–75
- Retinoic acid binding protein-ligand interactions, hydrogen/deuterium exchange mass spectrometry, 144
- Ribonucleic acid:
 - deoxyribonucleic acid to, 4–6
 - to protein, 6
- Ribosome display, chemical genomics, 242
- Robotic nanovolume crystallization, imaging and, high-throughput crystallography/in silico methods, 111–113
- Sample preparation, for mass spectrometry, protein-protein interaction mapping, 69–70
- Separation technique, electrospray ionization mass spectrometry, 36
- Signaling pathways, protein complexes and, biomarkers, 190–191
- Single-peptide-based identification, proteomics, gel-free analysis, 53–54
- Software, protein detection, two-dimensional gel electrophoresis (protein separation), 17
- Solid protein arrays, liquid versus, 275–277
- Spotting technologies, protein arrays, 279–280
- Structure-based drug design. *See* High-throughput crystallography/in silico methods
- Structure prediction, high-throughput crystallography/in silico methods, 123–125
- Subcellular components, protein purification, 11–12
- Subpopulation, of cells, protein purification, 10–11
- Surface-enhanced laser desorption/ionization mass spectrometry (SELDI/MS), 194–198
- Surfaces optimization, protein arrays, 277–279
- Tandem mass spectrum (MS/MS):
 - bioinformatics, protein identification, 46–49
 - deuterium sublocalization by, hydrogen/deuterium exchange mass spectrometry, 139
 - liquid chromatography, multidimensional, protein targets identification, 165
 - peptide masses and, protein-protein interaction mapping, protein identification based on, 71–73
 - targeted phosphopeptide sequencing and phosphosite mass spectrometry Western analysis by, protein posttranslational modifications, 88–89, 46–49
- Targeted phosphopeptide sequencing and phosphosite mass spectrometry Western analysis by LC-ES-MS/MS, protein posttranslational modifications, 88–89
- Therapeutic proteins analysis, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 146–148
- Thioredoxin, glutathione-thioredoxin conjugates, hydrogen/deuterium exchange mass spectrometry, applications without fragmentation, 143–144
- Thrombin antibodies, hydrogen/deuterium exchange mass spectrometry, applications with fragmentation, 152
- Translational modifications. *See* Protein posttranslational modifications
- Triple quadrupole mass spectrometer, electrospray ionization mass spectrometry, 28–30

- Two-dimensional gel electrophoresis,
 - 12–17
 - principles of, 13–15
 - protein detection, 15–17
 - protein targets identification, 162
- 2-hybrid method, protein-protein interaction mapping, 79–80
- Whey proteins, hydrogen/deuterium exchange mass spectrometry, applications without fragmentation, 144–145
- X-ray data collection, high-throughput crystallography/in silico methods, 114–115

